4-(Methylsulfonyl)phenylacetic Acid CAS 90536-66-6 Purity >99.5% (HPLC) Etoricoxib Intermediate Factory
Leading Manufacturer and Supplier, Intermediates of Etoricoxib
Etoricoxib API CAS 202409-33-4
4-(Methylthio)Phenylacetic Acid CAS 16188-55-9
4-(Methylsulfonyl)Phenylacetic Acid CAS 90536-66-6
Please contact: alvin@ruifuchem.com
| Chemical Name | 4-(Methylsulfonyl)phenylacetic Acid |
| Synonyms | 4-Methylsulphonylphenylacetic Acid; 4-(Methanesulfonyl)phenylacetic Acid; (4-Methanesulfonylphenyl)acetic Acid; 4-Methylsulfonyl Phenyl Acetic Acid; 2-(4-(Methylsulfonyl)phenyl)acetic Acid; [p-(Methylsulfonyl)phenyl]-Acetic Acid; 4-Mesylphenylacetic Acid |
| CAS Number | 90536-66-6 |
| CAT Number | RF-PI1182 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C9H10O4S |
| Molecular Weight | 214.24 |
| Melting Point | 136.0 to 140.0℃ |
| Density | 1.35 |
| Solubility | Soluble in Methanol |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Solid Powder |
| Purity / Analysis Method | >99.5% (HPLC) |
| Melting Point | 136.0 to 140.0℃ |
| Moisture (K.F) | <0.50% |
| Single Largest Impurity | <0.30% |
| Total Impurities | <0.50% |
| Infrared Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Etoricoxib (CAS: 202409-33-4) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
4-(Methylsulfonyl)phenylacetic Acid (CAS: 90536-66-6) is an intermediate of Etoricoxib (CAS: 202409-33-4). Etoricoxib is a kind of highly selective cyclooxygenase-2 (COX-2) inhibitors developed by the Merck company. Etoricoxib is widely used in treatment of osteoarthritis (OA), rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gouty arthritis, primary dysmenorrhea and postoperative pain, and other diseases. Etoricoxib, a selective COX-2 inhibitor, has anti-inflammatory, analgesic and antipyretic effects, suitable for the treatment of symptoms and signs of acute and chronic osteoarthritis, as well as acute gouty arthritis. Etoricoxib is rapidly absorbed, with an oral bioavailability of 80 to 100%, and reaches maximum plasma concentrations in 1 to 2 hours after dosing. Food decreases the rate of absorption but has no effect on the extent of absorption. It exhibits a long elimination half-life of approximately 22 hours, demonstrating linear plasma pharmacokinetics with no accumulation during multiple dosing.
